Articles dans des revues avec comité de lecture (183)
2.
Gilloteaux, J., De Swert, K., Suain, V., Brion, J. P., & Nicaise, C. (2023). Loss of Ephaptic Contacts in the Murine Thalamus during Osmotic Demyelination Syndrome. Ultrastructural pathology, 47(5), 398-423. doi:10.1080/01913123.2023.22324523.
Ando, K., Nagaraj, S., Küçükali, F., De Fisenne, M.-A., Kosa, A.-C., Doeraene, E., López Gutiérrez, L., Brion, J. P., & Leroy, K. (2022). PICALM and Alzheimer’s Disease: An Update and Perspectives. Cells, 11(24), 3994. doi:10.3390/cells112439944.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau aggregates do not spread tau pathology to the brain via the Retino-tectal projection after intraocular injection in male mouse models. Neurobiology of disease, 174, 105875. doi:10.1016/j.nbd.2022.1058755.
Sáez-Orellana, F., Leroy, T., Ribeiro, F., Kreisler, A., Leroy, K., Lalloyer, F., Baugé, E., Staels, B., Duyckaerts, C., Brion, J. P., Gailly, P., Octave, J. N., & Pierrot, N. (2021). Regulation of PPARα by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity. JCI insight, 6(16). doi:10.1172/jci.insight.1500996.
Sexton, C., Snyder, H., Beher, D., Boxer, A. A., Brannelly, P., Brion, J. P., Buée, L., Cacace, A. A., Chételat, G., Citron, M., DeVos, S. L., Diaz, K., Feldman, H. H., Frost, B., Goate, A. A., Gold, M., Hyman, B., Johnson, M. K., Karch, C. M., Kerwin, D. D., Koroshetz, W. W., Litvan, I., Morris, H. R., Mummery, C. C., Mutamba, J., Patterson, M. M., Quiroz, Y. Y., Rabinovici, G. D., Rommel, A., Shulman, M. M., Toledo-Sherman, L. L., Weninger, S., Wildsmith, K. K., Worley, S. S., & Carrillo, M. M. (2021). Current directions in tau research: Highlights from Tau 2020. Alzheimer's & Dementia, 18, 988-1007. doi:10.1002/alz.124527.
Gilloteaux, J., Bouchat, J., Bielarz, V., Brion, J. P., & Nicaise, C. (2021). A primary cilium in oligodendrocytes: a fine structure signal of repairs in thalamic Osmotic Demyelination Syndrome (ODS). Ultrastructural pathology, 45(2), 128-157. doi:10.1080/01913123.2021.18911618.
Ando, K., Erneux, C., Homa, M., Houben, S., De Fisenne, M.-A., Brion, J. P., & Leroy, K. (2021). Dysregulation of Phosphoinositide 5-Phosphatases and Phosphoinositides in Alzheimer's Disease. Frontiers in Neuroscience, 15, 614855. doi:10.3389/fnins.2021.6148559.
Houben, S., Homa, M., Yilmaz, Z., Leroy, K., Brion, J. P., & Ando, K. (2021). Tau Pathology and Adult Hippocampal Neurogenesis: What Tau Mouse Models Tell us? Frontiers in neurology, 12, 610330. doi:10.3389/fneur.2021.61033011.
Houben, S., De Fisenne, M.-A., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2020). Intravenous injection of PHF-Tau proteins from Alzheimer Brain exacerbates neuroinflammation, Amyloid beta, and tau pathologies in 5XFAD transgenic mice. Frontiers in Molecular Neuroscience, 13, 10.3389/fnmol.2020.00106, 106.12.
Ando, K., Ferlini, L., Suain, V., Yilmaz, Z., Mansour, S., Le Ber, I., Bouchard, C., Leroy, K., Durr, A., Clot, F., Sarazin, M., Bier, J. C., & Brion, J. P. (2020). de novo MAPT mutation G335A causes severe brain atrophy, 3R and 4R PHF-tau pathology and early onset frontotemporal dementia. Acta neuropathologica communications, 8(1), 94. doi:10.1186/s40478-020-00977-813.
Ando, K., De Decker, R., Vergara Panos, C., Yilmaz, Z., Mansour, S., Suain, V., Sleegers, K., De Fisenne, M.-A., Houben, S., Potier, M.-C., Duyckaerts, C., Watanabe, T., Buée, L., Leroy, K., & Brion, J. P. (2020). Picalm reduction exacerbates tau pathology in a murine tauopathy model. Acta Neuropathologica, 139(4), 773-789. doi:10.1007/s00401-020-02125-x